+1-888-308-5802     
News Contact Us

Innate Pharma and AstraZeneca extend oncology development partnership

Author : Pankaj Singh | Published Date : 2018-10-24 

Innate Pharma SA has reportedly announced a multi-term agreement with AstraZeneca and its global biologics research and development subsidiary, MedImmune. Innate looks to building on an existing collaboration to accelerate the oncology portfolio of each company and bring new medicines to patients faster.

Apparently, Innate will be able to develop its commercial footprint and solidify its capability to invest in its immuno-oncology (IO) pipeline and R&D platform. It will also enrich the IO portfolio of AstraZeneca with preclinical and clinical potential new medicines.

As part of the agreement, Innate is licensing the EU and US commercial rights to AstraZeneca’s Lumoxiti (moxetumomab pasudotox-tdfk) which was recently FDA-approved for hairy cell leukemia ("HCL"). AstraZeneca, in turn, will obtain full oncology rights to monalizumab, the first-in-class humanized anti-NKG2A antibody. AstraZeneca further gains option rights to four pre-clinical molecules from the pipeline of Innate along with IPH5201, an antibody targeting CD39.

Chief Executive of Innate Pharma, Mondher Mahjoubi, stated that the company is transitioning to become a fully-integrated biotech focused on oncology. The company is addressing significant unmet medical needs like relapsed/refractory hairy cell leukemia, and Lumoxiti is a therapeutic innovation for patients suffering from these diseases, he added.

Mahjoubi said the company’s commercial team will focus on rare cancers and generate more value with the development of its hemato-oncology proprietary pipeline. Moreover, the decision of AstraZeneca to collaborate on IPH5201 and four yet to be selected molecules, in addition to obtaining full oncology rights to monalizumab justifies the strength of Innate’s oncology pipeline, he mentioned.

Chief Executive of AstraZeneca, Pascal Soriot, said that the expanded alliance with Innate enables AstraZeneca to explore the potential of next generation immuno-oncology pathways, and further strengthen its leadership in immuno-oncology with Innate’s world-class scientific team. This collaboration also secures long-term commercialization of Lumoxiti through dedicated focus and investment by Innate.

For the record, AstraZeneca will acquire an equity stake of 9.8% in Innate Pharma via 6,260,500 new shares issued to AstraZeneca at €10 per share, under the long-term collaboration among the two companies.

About Author

Pankaj Singh

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Cymulate’s BAS platform bags $7.5M in Series A financing round

Published Date: 2019-03-15         Author: Pankaj Singh

The investment will be used to expand Cymulate’s U.S. operations and to enhance its platform’s functionality. Israel-based cybersecurity firm, Cymulate Ltd. has recently raised around $7.5 million in a Series A financing round led by Dell Technologies Capital and Vertex Ventures ... Read More

Rubber processing chemicals industry to exhibit an accelerated growth rate from tire manufacturing applications to 2025, surging automobile production to fuel the industry landscape

Published Date: 2019-02-26         Author: Pankaj Singh

Owing to the ceaseless demand for automobiles over the past three decades, the global rubber processing chemicals industry has witnessed rapid development, specifically from the tire manufacturing segment. A rather fast moving vertical, tire manufacturing involves continuous utilization of chemicals... Read More

Automotive Gesture Recognition Technology: The Next Level in Road Safety

Published Date: 2019-02-26         Author: Pankaj Singh

The growing sales of luxury cars having advanced safety and comfort features have fueled the development of the automotive gesture recognition market, as automakers seek to incorporate more technologies for improving overall driving experience. Gesture control not only makes using various in-built s... Read More

© 2019 Fractovia. All Rights Reserved